肺部肿瘤立体定向消融放疗后窦房结毒性
该回顾性研究分析了2008至2014年接受右侧中央型肺部肿瘤立体定向消融放疗(SABR)的患者,其中13例窦房结受照剂量超过处方剂量的10%。
要点
- 右侧中央型肺肿瘤SABR可能使窦房结受到有临床意义的照射剂量。
- 窦房结毒性虽罕见,但可表现为需起搏器置入的病态窦房结综合征。
- 建议对窦房结受照剂量较高的患者进行心脏毒性随访。
核心结论
- 右侧中央型胸部肿瘤SABR后窦房结毒性不常见,但应被认识和进一步研究。
研究设计与样本
- 共回顾47例右侧中央型肿瘤患者,其中13例符合研究标准,平均随访28个月。
主要发现
- 1例右肺门非小细胞肺癌患者SABR后6个月出现有症状的病态窦房结综合征,需置入起搏器。
- 该患者急性表现及SABR至症状出现的短间隔提示窦房结毒性可能源于放射性损伤。
- 该患者年龄和窦房结平均剂量均居队列第三高,24个月随访时无肿瘤进展。
关键数值与推荐
- 研究纳入窦房结受照剂量超过处方剂量10%的患者。
- 中央型肿瘤定义为距主支气管或其他纵隔结构2 cm以内。
临床怎么用
- 对右侧中央型肺肿瘤行SABR时,应关注窦房结受照剂量并记录。
- 治疗后随访中需警惕窦房结功能障碍相关症状,必要时转诊心脏专科。
局限性
- 回顾性研究,样本量小,仅13例符合标准。
- 窦房结毒性事件仅1例,无法确定剂量-效应关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic ablative radiation therapy (SABR) is an established treatment for selected lung tumors. Sinoatrial node (SAN) toxicity after thoracic SABR has not been reported in the literature. We sought to understand the risk of SAN toxicity owing to incidental dose to the SAN from SABR. METHODS AND MATERIALS: We conducted a retrospective review of patients with early-stage lung cancer or limited pulmonary metastases who underwent thoracic SABR to a right-sided central lung tumor (within 2 cm of the mainstem bronchus or other mediastinal structures) between January 2008 and December 2014, analyzed a subset whose treatment imparted dose to the SAN exceeding 10% of the prescription dose, and examined patient and treatment dosimetric characteristics. Mean follow-up interval was 28 months. Time to toxicity was defined from start of SABR. RESULTS: Of 47 patients with central tumors in the right lung treated with SABR reviewed, 13 met our study criteria. A contouring atlas of regional cardiac anatomy was created. One patient treated with SABR for non-small cell lung cancer at the right hilum developed symptomatic sick sinus syndrome, requiring pacemaker placement 6 months after treatment. Her acute presentation and short interval between SABR and onset of symptoms suggest that SAN toxicity was likely due to radiation-induced injury. Both her age and mean dose to her SAN were the third highest in our cohort. She remained free from cancer progression at 24 months' follow-up. Twelve additional patients who received significant dose to the SAN from SABR did not develop toxicity. CONCLUSION: While uncommon, SAN toxicity from SABR to right-sided central thoracic tumors should be recognized and followed in future studies.
引用
- Qian Y, Zhu H, Pollom EL, et al. Sinoatrial node toxicity after stereotactic ablative radiation therapy to lung tumors. Pract Radiat Oncol. 2017. PMID: 28669706. doi:10.1016/j.prro.2017.04.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。